Benefit of Biennial Fecal Occult Blood Screening on Colorectal Cancer in England: A Population-Based Case-Control Study.
Journal
Journal of the National Cancer Institute
ISSN: 1460-2105
Titre abrégé: J Natl Cancer Inst
Pays: United States
ID NLM: 7503089
Informations de publication
Date de publication:
09 09 2022
09 09 2022
Historique:
received:
31
08
2021
revised:
23
11
2021
accepted:
06
05
2022
pubmed:
17
5
2022
medline:
15
9
2022
entrez:
16
5
2022
Statut:
ppublish
Résumé
The English national bowel cancer screening program offering a guaiac fecal occult blood test began in July 2006. In randomized controlled trials of guaiac fecal occult blood test screening, reductions in mortality were accompanied by reductions in advanced stage colorectal cancer (CRC). We aimed to evaluate the effect of participation in the national bowel cancer screening program on stage-specific CRC incidence as a likely precursor of a mortality effect. In this population-based case-control study, cases were individuals diagnosed with CRC aged 60-79 years between January 1, 2012, and December 31, 2013. Two controls per case were matched on geographic region, gender, date of birth, and year of first screening invitation. Screening histories were extracted from the screening database. Conditional logistic regression with correction for self-selection bias was used to estimate odds ratios (odds ratios corrected for self-selection bias [cOR]) and 95% confidence intervals (CIs) by Duke stage, sex, and age. 14 636 individuals with CRC and 29 036 without were eligible for analysis. The odds of CRC (any stage) were increased within 30 days of a screening test and decreased thereafter. No reduction in CRC (any stage) among screened individuals compared with those not screened was observed (cOR = 1.00, 95% CI = 0.89 to 1.15). However, screened individuals had lower odds of Duke stage D CRC (cOR = 0.68, 95% CI = 0.50 to 0.93). We estimate 435 fewer Duke D CRC by age 80 years in 100 000 people screened biennially between ages 60 and 74 years compared with an unscreened cohort. The impact of colorectal screening on advanced CRC incidence suggests that the program will meet its aim of reducing mortality.
Sections du résumé
BACKGROUND
The English national bowel cancer screening program offering a guaiac fecal occult blood test began in July 2006. In randomized controlled trials of guaiac fecal occult blood test screening, reductions in mortality were accompanied by reductions in advanced stage colorectal cancer (CRC). We aimed to evaluate the effect of participation in the national bowel cancer screening program on stage-specific CRC incidence as a likely precursor of a mortality effect.
METHODS
In this population-based case-control study, cases were individuals diagnosed with CRC aged 60-79 years between January 1, 2012, and December 31, 2013. Two controls per case were matched on geographic region, gender, date of birth, and year of first screening invitation. Screening histories were extracted from the screening database. Conditional logistic regression with correction for self-selection bias was used to estimate odds ratios (odds ratios corrected for self-selection bias [cOR]) and 95% confidence intervals (CIs) by Duke stage, sex, and age.
RESULTS
14 636 individuals with CRC and 29 036 without were eligible for analysis. The odds of CRC (any stage) were increased within 30 days of a screening test and decreased thereafter. No reduction in CRC (any stage) among screened individuals compared with those not screened was observed (cOR = 1.00, 95% CI = 0.89 to 1.15). However, screened individuals had lower odds of Duke stage D CRC (cOR = 0.68, 95% CI = 0.50 to 0.93). We estimate 435 fewer Duke D CRC by age 80 years in 100 000 people screened biennially between ages 60 and 74 years compared with an unscreened cohort.
CONCLUSION
The impact of colorectal screening on advanced CRC incidence suggests that the program will meet its aim of reducing mortality.
Identifiants
pubmed: 35575409
pii: 6586300
doi: 10.1093/jnci/djac100
pmc: PMC9468279
doi:
Substances chimiques
Guaiac
9000-29-7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1262-1269Informations de copyright
© The Author(s) 2022. Published by Oxford University Press.
Références
Lancet. 1996 Nov 30;348(9040):1467-71
pubmed: 8942774
Int J Colorectal Dis. 2001 Sep;16(5):313-7
pubmed: 11686530
Eur J Cancer. 1999 Jun;35(6):973-7
pubmed: 10533481
Br J Cancer. 2012 Aug 21;107(5):757-64
pubmed: 22850549
Ann Oncol. 2003 Aug;14(8):1190-2
pubmed: 12881374
Lancet Oncol. 2020 Jan;21(1):73-79
pubmed: 31704137
Br J Surg. 2008 Aug;95(8):1029-36
pubmed: 18563785
Gut. 2012 Oct;61(10):1439-46
pubmed: 22156981
Prev Med. 2011 Sep;53(3):131-3
pubmed: 21658405
Stat Methods Med Res. 2013 Jun;22(3):278-95
pubmed: 21220355
Am J Epidemiol. 2000 May 15;151(10):991-8
pubmed: 10853638
N Engl J Med. 2018 May 03;378(18):1734-1740
pubmed: 29580179
Br J Cancer. 2003 Jul 7;89(1):23-8
pubmed: 12838295
Front Oncol. 2021 Mar 15;11:620644
pubmed: 33791207
J Natl Cancer Inst. 1999 Mar 3;91(5):434-7
pubmed: 10070942
BMC Cancer. 2014 Dec 13;14:945
pubmed: 25495609
Intern Med J. 2016 Feb;46(2):166-71
pubmed: 26418334
BMJ. 2009 Jul 28;339:b2968
pubmed: 19638651
N Engl J Med. 2000 Nov 30;343(22):1603-7
pubmed: 11096167
Eur J Cancer Prev. 1993 May;2(3):221-7
pubmed: 8490540
J Med Screen. 2013;20(3):125-48
pubmed: 24197771
Colorectal Dis. 2010 May;12(5):420-2
pubmed: 19843116
Gut. 2012 Jul;61(7):1036-40
pubmed: 22052062
Med J Aust. 2013 Apr 1;198(6):327-30
pubmed: 23545032
Lancet. 1996 Nov 30;348(9040):1472-7
pubmed: 8942775
Eur J Cancer Prev. 2011 May;20(3):184-9
pubmed: 21301345
Br J Cancer. 2009 Dec 3;101 Suppl 2:S60-3
pubmed: 19956165